PT  - JOURNAL ARTICLE
AU  - Gonçalves, Bronner P.
AU  - Hall, Matthew
AU  - Jassat, Waasila
AU  - Balan, Valeria
AU  - Murthy, Srinivas
AU  - Kartsonaki, Christiana
AU  - Semple, Malcolm G.
AU  - Rojek, Amanda
AU  - Baruch, Joaquín
AU  - Reyes, Luis Felipe
AU  - Dasgupta, Abhishek
AU  - Dunning, Jake
AU  - Citarella, Barbara Wanjiru
AU  - Pritchard, Mark
AU  - Martín-Quiros, Alejandro
AU  - Sili, Uluhan
AU  - Baillie, J. Kenneth
AU  - Aryal, Diptesh
AU  - Arabi, Yaseen
AU  - Rashan, Aasiyah
AU  - Angheben, Andrea
AU  - Caoili, Janice
AU  - Carrier, François Martin
AU  - Harrison, Ewen M.
AU  - Gómez-Junyent, Joan
AU  - Figueiredo-Mello, Claudia
AU  - Douglas, James Joshua
AU  - Nor, Mohd Basri Mat
AU  - Chow, Yock Ping
AU  - Wong, Xin Ci
AU  - Bertagnolio, Silvia
AU  - Thwin, Soe Soe
AU  - Streinu-Cercel, Anca
AU  - Salazar, Leonardo
AU  - Rishu, Asgar
AU  - Rangappa, Rajavardhan
AU  - Ong, David S.Y.
AU  - Hashmi, Madiha
AU  - Carson, Gail
AU  - Diaz, Janet
AU  - Fowler, Rob
AU  - Kraemer, Moritz U.G.
AU  - Wils, Evert-Jan
AU  - Horby, Peter
AU  - Merson, Laura
AU  - Olliaro, Piero L.
AU  - ,
TI  - An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients
AID  - 10.1101/2022.06.22.22276764
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.22.22276764
4099  - http://medrxiv.org/content/early/2022/06/22/2022.06.22.22276764.short
4100  - http://medrxiv.org/content/early/2022/06/22/2022.06.22.22276764.full
AB  - Background Whilst timely clinical characterisation of infections caused by novel SARS-CoV-2 variants is necessary for evidence-based policy response, individual-level data on infecting variants are typically only available for a minority of patients and settings.Methods Here, we propose an innovative approach to study changes in COVID-19 hospital presentation and outcomes after the Omicron variant emergence using publicly available population-level data on variant relative frequency to infer SARS-CoV-2 variants likely responsible for clinical cases. We apply this method to data collected by a large international clinical consortium before and after the emergence of the Omicron variant in different countries.Results Our analysis, that includes more than 100,000 patients from 28 countries, suggests that in many settings patients hospitalised with Omicron variant infection less often presented with commonly reported symptoms compared to patients infected with pre-Omicron variants. Patients with COVID-19 admitted to hospital after Omicron variant emergence had lower mortality compared to patients admitted during the period when Omicron variant was responsible for only a minority of infections (odds ratio in a mixed-effects logistic regression adjusted for likely confounders, 0.67 [95% confidence interval 0.61 – 0.75]). Qualitatively similar findings were observed in sensitivity analyses with different assumptions on population-level Omicron variant relative frequencies, and in analyses using available individual-level data on infecting variant for a subset of the study population.Conclusions Although clinical studies with matching viral genomic information should remain a priority, our approach combining publicly available data on variant frequency and a multi-country clinical characterisation dataset with more than 100,000 records allowed analysis of data from a wide range of settings and novel insights on real-world heterogeneity of COVID-19 presentation and clinical outcome.Competing Interest StatementDalton, H. declares personal fees for medical director of Innovative ECMO Concepts and honorarium from Abiomed/BREETHE Oxi-1 and Instrumentation Labs. Consultant fee, Entegrion Inc., Medtronic and Hemocue. Dyrhol-Riise, AM, declares grants from Gilead outside this work. Donnelly, C.A. declares research funding from the UK Medical Research Council and the UK National Institute for Health Research. Douglas, J.J. declares personal fees from lectures from Sunovion and Merck; consulting fees from Pfizer. Guerguerian AM. Participated as site investigator for the Hospital For Sick Children, Toronto, Canada as a site through SPRINT-SARI Study via the Canadian Critical Care Trials Group sponsored in part by the Canadian Institutes of Health Research. Ho, A. declares grant funding from Medical Research Council UK, Scottish Funding Council - Grand Challenges Research Fund, and the Wellcome Trust, outside this submitted work. Holter, J.C. reports grants from Research Council of Norway grant no 312780, and from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the conduct of the study. Kumar, D. declares grants and personal fees from Roche, GSK and Merck; and personal fees from Pfizer and Sanofi. Kutsogiannis, D.J. declares personal fees for a lecture from Tabuk Pharmaceuticals and the Saudi Critical Care Society Lee, J. reports grants from European Commission PREPARE grant agreement No 602525, European Commission RECOVER Grant Agreement No 101003589 and European Commission ECRAID Grant Agreement 965313 supporting the conduct, coordination and management of the work. Lim, W.S. declares his institution has received unrestricted investigator-initiated research funding from Pfizer for an unrelated multicentre cohort study in which he is the Chief Investigator, and research funding from the National Institute for Health Research, UK for various clinical trials outside the submitted work. Martin-Loeches I. declared lectures for Gilead, Thermofisher, MSD; advisory board participation for Fresenius Kabi, Advanz Pharma, Gilead, Accelerate, Merck; and consulting fees for Gilead outside of the submitted work. Martín-Quiros, A. declares consulting fees for Gilead and advisory board participation in MSD and Gilead Murthy, S declares receiving salary support from the Health Research Foundation and Innovative Medicines Canada Chair in Pandemic Preparedness Research. Nichol, A. declares a grant from the Health Research Board of Ireland to support data collection in Ireland (CTN-2014-012), an unrestricted grant from BAXTER for the TAME trial kidney substudy and consultancy fees paid to his institution from AM-PHARMA. Openshaw, P. has served on scientific advisory boards for Janssen/J&J, Oxford Immunotech Ltd, GSK, Nestle and Pfizer (fees to Imperial College). He is Imperial College lead investigator on EMINENT, a consortium funded by the MRC and GSK. He is a member of the RSV Consortium in Europe (RESCEU) and Inno4Vac, Innovative Medicines Initiatives (IMI) from the European Union. Parke, R. declares that the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, receives support by way of an unrestricted grant from Fisher and Paykel Healthcare New Zealand Ltd. Rewa, O. declares honoraria from Baxter Healthcare Inc and Leading Biosciences Inc. S?ndulescu, O. has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, Celltrion, Inc. and Atriva Therapeutics, outside the scope of the submitted work. Semple, M.G. reports grants from DHSC National Institute of Health Research UK, from the Medical Research Council UK, and from the Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, supporting the conduct of the study; other interest in Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. Shrapnel, S. participated as an investigator for an observational study analysing ICU patients with COVID-19 (for the Critical Care Consortium including ECMOCARD) funded by The Prince Charles Hospital Foundation during the conduct of this study. Streinu-Cercel, Adrian has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, and Celltrion, Inc., outside the scope of the submitted work. Streinu-Cercel, Anca has been an investigator in COVID-19 clinical trials by Algernon Pharmaceuticals, Atea Pharmaceuticals, Regeneron Pharmaceuticals, Diffusion Pharmaceuticals, Celltrion, Inc. and Atriva Therapeutics, outside the scope of the submitted work. Summers, C. reports that she has received fees for consultancy for Abbvie and Roche relating to COVID-19 therapeutics. She was also the UK Chief Investigator of a GlaxoSmithKline plc sponsored study of a therapy for COVID, and is a member of the UK COVID Therapeutic Advisory Panel (UK-CTAP). Outside the scope of this work, Dr Summers' institution receives research grants from the Wellcome Trust, UKRI/MRC, National Institute for Health Research (NIHR), GlaxoSmithKline and AstraZeneca to support research in her laboratory. Susanne Dudman reports grants from Research Council of Norway grant no 312780. Tedder, R. reports grants from MRC/UKRI during the conduct of the study. In addition, R. Tedder has a patent United Kingdom Patent Application No. 2014047.1 "SARS-CoV-2 antibody detection assay" issued. Turtle, L. reports grants from MRC/UKRI during the conduct of the study and fees from Eisai for delivering a lecture related to COVID-19 and cancer, paid to the University of Liverpool.Funding StatementThis works was made possible with the support of UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z and 225288/Z/22/Z] and the Bill & Melinda Gates Foundation [OPP1209135]; CIHR Coronavirus Rapid Research Funding Opportunity OV2170359 and was coordinated out of Sunnybrook Research Institute; Wellcome Trust fellowship [205228/Z/16/Z] and the National Institute for Health Research Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections (NIHR200907) at the University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford; Institute for Clinical Research (ICR), National Institutes of Health (NIH) supported by the Ministry of Health Malaysia; a grant from foundation Bevordering Onderzoek Franciscus; MUGK acknowledges funding from the Branco Weiss Fellowship, Google.org, the Oxford Martin School, the Rockefeller Foundation, and the European Union Horizon 2020 project MOOD (#874850). The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views of the European Commission. The COVID-19 Clinical Information Network (CO-CIN) data was collated by ISARIC4C Investigators. Data provision was supported by grants from: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), (award 200907), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award IS-BRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support. This work was supported by endorsement of the Irish Critical Care-Clinical Trials Group, co-ordinated in Ireland by the Irish Critical Care-Clinical Trials Network at University College Dublin and funded by the Health Research Board of Ireland [CTN-2014-12]; grants from Rapid European COVID-19 Emergency Response research (RECOVER) [H2020 project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313]; Cambridge NIHR Biomedical Research Centre; The dedication and hard work of the Groote Schuur Hospital Covid ICU Team, supported by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town; The dedication and hard work of the Norwegian SARS-CoV-2 study team. Research Council of Norway grant no 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; PJMO is supported by the UK's National Institute for Health Research (NIHR) via Imperial's Biomedical Research Centre (NIHR Imperial BRC), Imperial's Health Protection Research Unit in Respiratory Infections (NIHR HPRU RI), the Comprehensive Local Research Networks (CLRNs) and is an NIHR Senior Investigator (NIHR201385); Gender Equity Strategic Fund at University of Queensland, Artificial Intelligence for Pandemics (A14PAN) at University of Queensland, The Australian Research Council Centre of Excellence for Engineered Quantum Systems (EQUS, CE170100009), The Prince Charles Hospital Foundation, Australia; the South Eastern Norway Health Authority and the Research Council of Norway; and a grant from the Oxford University COVID-19 Research Response fund (grant 0009109).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee approval for this work was given by the World Health Organisation Ethics Review Committee (RPC571 and RPC572 on 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central Oxford C Research Ethics Committee in England (Ref 13/SC/0149) and the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the United Kingdom and the Human Research Ethics Committee (Medical) at the University of the Witwatersrand in South Africa as part of a national surveillance programme (M160667) collectively representing the majority of the data. Other institutional and national approvals are in place as per local requirements.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data that underpin this analysis are highly detailed clinical data on individuals hospitalised with COVID-19. Due to the sensitive nature of these data and the associated privacy concerns, they are available via a governed data access mechanism following review of a data access committee. Data can be requested via the IDDO COVID-19 Data Sharing Platform (http://www.iddo.org/covid-19). The Data Access Application, Terms of Access and details of the Data Access Committee are available on the website. Briefly, the requirements for access are a request from a qualified researcher working with a legal entity who have a health and/or research remit; a scientifically valid reason for data access which adheres to appropriate ethical principles. The full terms are at https://www.iddo.org/document/covid-19-data-access-guidelines. A small subset of sites who contributed data to this analysis have not agreed to pooled data sharing as above. In the case of requiring access to these data, please contact the corresponding author in the first instance who will look to facilitate access. Code used for statistical analysis and aggregated data used to generate figures are available: https://github.com/ISARICDataPlatform/Omicron.